Orkun Ozhelvaci

BioNTech (Germany)

SCHOLARLY PAPERS

1

DOWNLOADS

538

SSRN CITATIONS

0

CROSSREF CITATIONS

0

Scholarly Papers (1)

1.

Immunogenicity and Safety of BNT162b2 mRNA Vaccine in Chinese Adults: A Randomized Clinical Trial

Number of pages: 35 Posted: 19 May 2022
Fosun Pharma (USA), Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Taizhou People’s Hospital, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Taizhou Vaccine Clinical Research Center, Taizhou People’s Hospital, Fosun Pharma (China), Fosun Pharma (China), Taizhou Vaccine Clinical Research Center, Taizhou People’s Hospital, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology, Lianshui Center for Disease Control and Prevention, Lianshui Center for Disease Control and Prevention, Fosun Pharma (China), Fosun Pharma (China), Fosun Pharma (China), BioNTech (Germany), BioNTech (Germany), BioNTech (USA), Fosun Pharma (China), BioNTech (Germany), BioNTech (Germany), BioNTech (Germany), BioNTech (Germany), BioNTech (USA), BioNTech (USA), BioNTech (Germany), BioNTech (Germany), BioNTech (Germany) and Jiangsu Provincial Center for Disease Control and Prevention - NHC Key Laboratory of Enteric Pathogenic Microbiology
Downloads 538 (83,470)
Citation 1

Abstract:

Loading...

BNT162b2 mRNA vaccine, COVID-19, intramuscular injection, messenger RNA, neutralizing antibodies, SARS-CoV-2, vaccination